(Q38012237)

27 August 2017

title

Models for disease progression: new approaches and uses (English)

1 reference

27 August 2017

D R Mould

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

23 May 2012

1 reference

Clinical Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

125-131

1 reference

More efficient clinical trials through use of scientific model-based statistical tests

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Intention-to-treat analysis and the goals of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Quantitative disease, drug, and trial models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

How modeling and simulation have enhanced decision making in new drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Mathematics for understanding disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Advanced methods in meta-analysis: multivariate approach and meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Use of indirect and mixed treatment comparisons for technology assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Disease progression meta-analysis model in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Mechanism-based models for topotecan-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Modeling the effect of tumor size in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

Using Disease Progression Models as a Tool to Detect Drug Effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

inferred from DOI database lookup

7 January 2021

based on heuristic

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.53

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2012.53

1 reference

Dimensions Publication ID

27 August 2017

1010012084

0 references

1 reference